190 related articles for article (PubMed ID: 25431858)
1. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
Maderna A; Doroski M; Subramanyam C; Porte A; Leverett CA; Vetelino BC; Chen Z; Risley H; Parris K; Pandit J; Varghese AH; Shanker S; Song C; Sukuru SC; Farley KA; Wagenaar MM; Shapiro MJ; Musto S; Lam MH; Loganzo F; O'Donnell CJ
J Med Chem; 2014 Dec; 57(24):10527-43. PubMed ID: 25431858
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
Yokosaka S; Izawa A; Sakai C; Sakurada E; Morita Y; Nishio Y
Bioorg Med Chem; 2018 May; 26(8):1643-1652. PubMed ID: 29454703
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.
Singh SB
J Nat Prod; 2022 Mar; 85(3):666-687. PubMed ID: 35072477
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates.
Maderna A; Leverett CA
Mol Pharm; 2015 Jun; 12(6):1798-812. PubMed ID: 25697404
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.
Pettit GR; Hogan F; Toms S
J Nat Prod; 2011 May; 74(5):962-8. PubMed ID: 21534541
[TBL] [Abstract][Full Text] [Related]
6. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
Odlo K; Hentzen J; dit Chabert JF; Ducki S; Gani OA; Sylte I; Skrede M; Flørenes VA; Hansen TV
Bioorg Med Chem; 2008 May; 16(9):4829-38. PubMed ID: 18396050
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
Pettit GR; Melody N; Chapuis JC
J Nat Prod; 2017 Mar; 80(3):692-698. PubMed ID: 28211277
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity correlation of natural-product inspired cyclodepsipeptides stabilizing F-actin.
Tannert R; Milroy LG; Ellinger B; Hu TS; Arndt HD; Waldmann H
J Am Chem Soc; 2010 Mar; 132(9):3063-77. PubMed ID: 20148556
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of cyclodepsipeptide zygosporamide and its analogues.
Wang Y; Zhang F; Zhang Y; Liu JO; Ma D
Bioorg Med Chem Lett; 2008 Aug; 18(15):4385-7. PubMed ID: 18606540
[TBL] [Abstract][Full Text] [Related]
11. N-methylsansalvamide a peptide analogues. Potent new antitumor agents.
Liu S; Gu W; Lo D; Ding XZ; Ujiki M; Adrian TE; Soff GA; Silverman RB
J Med Chem; 2005 May; 48(10):3630-8. PubMed ID: 15887970
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of cytotoxic marine cyclodepsipeptide IB-01212 analogues.
Cruz LJ; Francesch A; Cuevas C; Albericio F
ChemMedChem; 2007 Jul; 2(7):1076-84. PubMed ID: 17514692
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic agents. 599. Total synthesis of dolastatin 16.
Pettit GR; Smith TH; Arce PM; Flahive EJ; Anderson CR; Chapuis JC; Xu JP; Groy TL; Belcher PE; Macdonald CB
J Nat Prod; 2015 Mar; 78(3):476-85. PubMed ID: 25689568
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains.
Dugal-Tessier J; Barnscher SD; Kanai A; Mendelsohn BA
J Nat Prod; 2017 Sep; 80(9):2484-2491. PubMed ID: 28885014
[TBL] [Abstract][Full Text] [Related]
15. Dolastatin 11 conformations, analogues and pharmacophore.
Ali MA; Bates RB; Crane ZD; Dicus CW; Gramme MR; Hamel E; Marcischak J; Martinez DS; McClure KJ; Nakkiew P; Pettit GR; Stessman CC; Sufi BA; Yarick GV
Bioorg Med Chem; 2005 Jul; 13(13):4138-52. PubMed ID: 15878670
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
Poncet J; Busquet M; Roux F; Pierré A; Atassi G; Jouin P
J Med Chem; 1998 Apr; 41(9):1524-30. PubMed ID: 9554885
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of pironetin analogues with simplified structure and study of their interactions with microtubules.
Marco JA; García-Pla J; Carda M; Murga J; Falomir E; Trigili C; Notararigo S; Díaz JF; Barasoain I
Eur J Med Chem; 2011 May; 46(5):1630-7. PubMed ID: 21396747
[TBL] [Abstract][Full Text] [Related]
18. Studies toward the total synthesis of Itralamide B and biological evaluation of its structural analogs.
Wang X; Lv C; Feng J; Tang L; Wang Z; Liu Y; Meng Y; Ye T; Xu Z
Mar Drugs; 2015 Apr; 13(4):2085-104. PubMed ID: 25871289
[TBL] [Abstract][Full Text] [Related]
19. A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death.
Gajula PK; Asthana J; Panda D; Chakraborty TK
J Med Chem; 2013 Mar; 56(6):2235-45. PubMed ID: 23445405
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
Akaiwa M; Dugal-Tessier J; Mendelsohn BA
Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
